CytoMed Therapeutics Ltd Files 20-F for FY2024

Ticker: GDTC · Form: 20-F · Filed: Apr 28, 2025 · CIK: 1873093

Cytomed Therapeutics LTD 20-F Filing Summary
FieldDetail
CompanyCytomed Therapeutics LTD (GDTC)
Form Type20-F
Filed DateApr 28, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: annual-report, sec-filing, pharmaceuticals

TL;DR

CytoMed Therapeutics filed its 20-F for 2024, check financials.

AI Summary

CytoMed Therapeutics Ltd filed its 20-F report for the fiscal year ending December 31, 2024. The company, previously known as CytoMed Therapeutics Pte. Ltd. until July 16, 2021, is based at #08-22 One Commonwealth, Singapore. The filing covers financial data and business operations for the period.

Why It Matters

This filing provides investors with a comprehensive overview of CytoMed Therapeutics' financial health and business activities for the past fiscal year, crucial for investment decisions.

Risk Assessment

Risk Level: low — The filing is a standard annual report (20-F) and does not contain immediate red flags or significant new disclosures that would indicate a high risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of CytoMed Therapeutics Ltd?

CytoMed Therapeutics Ltd is classified under 'Pharmaceutical Preparations' (SIC code 2834).

When did CytoMed Therapeutics Ltd change its name?

The company changed its name from CytoMed Therapeutics Pte. Ltd. on July 16, 2021.

What is the business address of CytoMed Therapeutics Ltd?

The business address is #08-22 One Commonwealth, 1 Commonwealth Lane, Singapore, 149544.

What fiscal year does this 20-F report cover?

This 20-F report covers the fiscal year ending December 31, 2024.

What is the SEC file number for CytoMed Therapeutics Ltd?

The SEC file number for CytoMed Therapeutics Ltd is 001-41677.

Filing Details

This Form 20-F (Form 20-F) was filed with the SEC on April 28, 2025 regarding CytoMed Therapeutics Ltd (GDTC).

View full filing on EDGAR

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing